Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-β-Lactamase (VIM) in a Murine Thigh Infection Model | Zendy

Islam M. Ghazi | Zendy; Jared L. Crandon | Zendy; Emil Lesho | Zendy; Patrick McGann | Zendy; David P. Nicolau | Zendy

Open Access

Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-β-Lactamase (VIM) in a Murine Thigh Infection Model

Author(s) -

Islam M. Ghazi,

Jared L. Crandon,

Emil Lesho,

Patrick McGann,

David P. Nicolau

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00794-15

Subject(s) - cefepime , meropenem , enterobacteriaceae , microbiology and biotechnology , integron , biology , levofloxacin , antibacterial agent , antibiotics , antibiotic resistance , imipenem , gene , escherichia coli , genetics

We aimed to describe thein vivo activity of humanized pharmacokinetic exposures of meropenem and comparators against Verona integron-encoded metallo-β-lactamase (MBL) (VIM)-producingEnterobacteriaceae in a murine model. Levofloxacin activity was predicted by its MIC, and cefepime activity displayed variability, whereas meropenem produced a >1 log CFU reduction against all isolates despite high MICs indicative of resistance. Our results suggest that despitein vitro resistance, high-dose meropenem may be a possible option against infections caused byEnterobacteriaceae producing MBL-type carbapenemases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research